CD19 and diffuse large B-cell lymphoma: Consistently, a recent publication that includes results coming from a phase I clinical trial (NCT03144583) and compassionate use of anti-CD19 ARI-0001 CAR-T cells has documented favorable outcomes for the few DLBCL-type RS patients, reporting an ORR and CR rate of 60% [146].